TD Cowen Lowers Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $195.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective reduced by TD Cowen from $200.00 to $195.00 in a research report released on Thursday,Benzinga reports. TD Cowen currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other analysts also recently commented on the stock. Robert W. Baird dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, Royal Bank of Canada boosted their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, October 23rd. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $175.00.

Jazz Pharmaceuticals Trading Up 3.8 %

JAZZ traded up $4.53 during mid-day trading on Thursday, hitting $123.61. The stock had a trading volume of 868,107 shares, compared to its average volume of 525,365. The stock’s fifty day simple moving average is $110.64 and its 200-day simple moving average is $109.78. The firm has a market capitalization of $7.63 billion, a price-to-earnings ratio of 17.41, a price-to-earnings-growth ratio of 1.40 and a beta of 0.57. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $5.86 earnings per share for the quarter, topping the consensus estimate of $4.54 by $1.32. Jazz Pharmaceuticals had a return on equity of 30.16% and a net margin of 11.60%. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.04 billion. As a group, research analysts forecast that Jazz Pharmaceuticals will post 16.02 EPS for the current fiscal year.

Insider Activity

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Capital World Investors acquired a new position in shares of Jazz Pharmaceuticals in the first quarter valued at about $171,943,000. Swedbank AB acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $106,936,000. Rubric Capital Management LP bought a new position in shares of Jazz Pharmaceuticals during the second quarter worth approximately $65,812,000. Pacer Advisors Inc. raised its position in shares of Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after buying an additional 527,187 shares in the last quarter. Finally, Baupost Group LLC MA boosted its stake in shares of Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after buying an additional 440,552 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.